Clinical Trials Logo

Secondary Hyperparathyroidism clinical trials

View clinical trials related to Secondary Hyperparathyroidism.

Filter by:

NCT ID: NCT00123461 Completed - Renal Failure Clinical Trials

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Start date: July 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate the safety and effectiveness of Hectorol® (doxercalciferol) capsules in treating patients with Stage 3 or Stage 4 chronic kidney disease (CKD) with secondary hyperparathyroidism who have vitamin D levels in the normal range. Previous studies with doxercalciferol were conducted in patients who had low levels of vitamin D.

NCT ID: NCT00117052 Completed - Clinical trials for End Stage Renal Disease

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.

NCT ID: NCT00073710 Completed - Clinical trials for Chronic Kidney Disease

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

Start date: September 2004
Phase: Phase 4
Study type: Interventional

A study to investigate the effects of Zemplar and Calcijex on intestinal calcium absorption in hemodialysis subjects.

NCT ID: NCT00053547 Completed - Clinical trials for End Stage Renal Disease

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

Start date: January 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.

NCT ID: NCT00042653 Completed - Clinical trials for End Stage Renal Disease

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis

Start date: May 2002
Phase: Phase 3
Study type: Interventional

This 6 month study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.

NCT ID: NCT00042432 Completed - Clinical trials for Secondary Hyperparathyroidism

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Start date: June 2002
Phase: Phase 2
Study type: Interventional

This study will assess an investigational medication for patients with chronic renal insufficiency (pre-dialysis) who have secondary hyperparathyroidism.

NCT ID: NCT00037635 Completed - Clinical trials for End Stage Renal Disease

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

Start date: December 2001
Phase: Phase 3
Study type: Interventional

This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.

NCT ID: NCT00037193 Completed - Clinical trials for Secondary Hyperparathyroidism

Acute Regulation of Parathyroid Hormone by Dietary Phosphate

Start date: n/a
Phase: N/A
Study type: Observational

Patients with end stage renal disease often have secondary hyperparathyroidism due to high phosphorus and low calcium levels in the blood. Preliminary animal studies and our initial human study indicate that the parathyroid hormone levels may change quickly based on the ingestion of phosphorus, prior to any change in the blood levels of calcium or phosphorus. This follow-up study will attempt to determine if the effect is independent of an increase in the blood glucose level. If so, this would suggest an as yet unidentified gastrointestinal receptor that mediates parathyroid hormone levels. This may affect the timing of administration and the type of phosphate binder used in treating patients with secondary hyperparathyroidism. The knowledge that parathyroid hormone levels can change acutely may also affect the recommended timing of blood samples